DNA repair targeting and radiotherapy: A focus on the therapeutic ratio

Seminars in Radiation Oncology

Volumn 20, Issue 4, 2010, Pages 217-222

  Thoms, John ^a,b   Bristow, Robert G ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN;

BRACHYTHERAPY; CANCER RADIOTHERAPY; CELL CYCLE; CELL HYPOXIA; DNA REPAIR; DOUBLE STRANDED DNA BREAK; GERM LINE; HUMAN; IMAGE GUIDED RADIOTHERAPY; PRIORITY JOURNAL; REVIEW; SINGLE STRANDED DNA BREAK; SOMATIC MUTATION; TUMOR CELL;

CLINICAL TRIALS AS TOPIC; DNA BREAKS, DOUBLE-STRANDED; DNA DAMAGE; DNA REPAIR; DNA, NEOPLASM; DOSE FRACTIONATION; DOSE-RESPONSE RELATIONSHIP, RADIATION; HUMANS; INDIVIDUALIZED MEDICINE; MUTATION; NEOPLASMS; RADIATION ONCOLOGY; RADIOTHERAPY DOSAGE;

EID: 77956458848     PISSN: 10534296     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semradonc.2010.06.003     Document Type: Review

References (38)

1. Bristow R.G., Ozcelik H., Jalali F., et al. Homologous recombination and prostate cancer: A model for novel DNA repair targets and therapies. Radiother Oncol 2007, 83:220-230.
2. Begg A.C. Predicting response to radiotherapy: Evolutions and revolutions. Int J Radiat Biol 2009, 85:825-836.
3. Bentzen S.M. Preventing or reducing late side effects of radiation therapy: Radiobiology meets molecular pathology. Nat Rev Cancer 2006, 6:702-713.
4. Bentzen S.M., Trotti A. Evaluation of early and late toxicities in chemoradiation trials. J Clin Oncol 2007, 25:4096-4103.
5. Bentzen S.M. From cellular to high-throughput predictive assays in radiation oncology: challenges and opportunities. Semin Radiat Oncol 2008, 18:75-88.
6. Chan N., Koch C.J., Bristow R.G. Tumor hypoxia as a modifier of DNA strand break and cross-link repair. Curr Mol Med 2009, 9:401-410.
7. Brown J.M., Wilson W.R. Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer 2004, 4:437-447.
8. Nichol A.M., Warde P., Bristow R.G. Optimal treatment of intermediate-risk prostate carcinoma with radiotherapy: Clinical and translational issues. Cancer 2005, 104:891-905.
9. Choudhury A., Cuddihy A., Bristow R.G. Radiation and new molecular agents. part I: Targeting ATM-ATR checkpoints, DNA repair, and the proteasome. Semin Radiat Oncol 2006, 16:51-58.
10. Helleday T., Petermann E., Lundin C., et al. DNA repair pathways as targets for cancer therapy. Nat Rev Cancer 2008, 8:193-204.
11. Ashworth A. A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J Clin Oncol 2008, 26:3785-3790.
12. Damaraju S., Murray D., Dufour J., et al. Association of DNA repair and steroid metabolism gene polymorphisms with clinical late toxicity in patients treated with conformal radiotherapy for prostate cancer. Clin Cancer Res 2006, 12:2545-2554.
13. West C.M., Elliott R.M., Burnet N.G. The genomics revolution and radiotherapy. Clin Oncol R Coll Radiol 2007, 19:470-480.
14. Bartek J., Lukas J. DNA damage checkpoints: from initiation to recovery or adaptation. Curr Opin Cell Biol 2007, 19:238-245.
15. Chalmers A.J. Poly(ADP-ribose) polymerase-1 and ionizing radiation: Sensor, signaler and therapeutic target. Clin Oncol R Coll Radiol 2004, 16:29-39.
16. Loser D.A., Shibata A., Shibata A.K., et al. Sensitization to radiation and alkylating agents by inhibitors of poly(ADP-ribose) polymerase is enhanced in cells deficient in DNA double-strand break repair. Mol Cancer Ther 2010, 9:1775-1787.
17. Neijenhuis S., Verwijs-Janssen M., Kasten-Pisula U., et al. Mechanism of cell killing after ionizing radiation by a dominant negative DNA polymerase beta. DNA Repair (Amst) 2009, 8:336-346.
18. Helleday T. DNA double-strand break repair: from mechanistic understanding to cancer treatment. DNA Repair (Amst) 2007, 6:923-935.
19. Bryant H.E., Schultz N., Thomas H.D., et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005, 434:913-917.
20. Farmer H., McCabe N., Lord C.J., et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005, 434:917-921.
21. Fong P.C., Boss D.S., Yap T.A., et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009, 361:123-134.
22. Lord C.J., Ashworth A. Targeted therapy for cancer using PARP inhibitors. Curr Opin Pharmacol 2008, 8:363-369.
23. Martin S.A., McCabe N., Mullarkey M., et al. DNA polymerases as potential therapeutic targets for cancers deficient in the DNA mismatch repair proteins MSH2 or MLH1. Cancer Cell 2010, 17:235-248.
24. Mendes-Pereira A.M., Martin S.A., Brough R., et al. Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. EMBO Mol Med 2009, 1:315-322.
25. Sourisseau T., Maniotis D., McCarthy A., et al. Aurora-A expressing tumour cells are deficient for homology-directed DNA double strand-break repair and sensitive to PARP inhibition. EMBO Mol Med 2010, 2:130-142.
26. Kennedy R.D., Chen C.C., Stuckert P., et al. Fanconi anemia pathway-deficient tumor cells are hypersensitive to inhibition of ataxia telangiectasia mutated. J Clin Invest 2007, 117:1440-1449.
27. Das A.K., Chen B.P., Story M.D., et al. Somatic mutations in the tyrosine kinase domain of epidermal growth factor receptor (EGFR) abrogate EGFR-mediated radioprotection in non-small cell lung carcinoma. Cancer Res 2007, 67:5267-5274.
28. Ishkanian A.S., Mallof C.A., Ho J., et al. High-resolution array CGH identifies novel regions of genomic alteration in intermediate-risk prostate cancer. Prostate 2009, 69:1091-1100.
29. Supiot S., Hill R.P., Bristow R.G. Nutlin-3 radiosensitizes hypoxic prostate cancer cells independent of p53. Mol Cancer Ther 2008, 7:993-999.
30. Supiot S., Zhao H., Wiman K., et al. PRIMA-1(met) radiosensitizes prostate cancer cells independent of their MTp53-status. Radiother Oncol 2008, 86:407-411.
31. McCabe N., Turner N.C., Lord C.J., et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res 2006, 66:8109-8115.
32. Bhogal N., Jalali F., Bristow R.G. Microscopic imaging of DNA repair foci in irradiated normal tissues. Int J Radiat Biol 2009, 85:732-746.
33. Bristow R.G., Hill R.P. Hypoxia and metabolism. Hypoxia, DNA repair and genetic instability. Nat Rev Cancer 2008, 8:180-192.
34. Sprong D., Janssen H.L., Vens C., et al. Resistance of hypoxic cells to ionizing radiation is influenced by homologous recombination status. Int J Radiat Oncol Biol Phys 2006, 64:562-572.
35. Chan N., Koritzinsky M., Zhao H., et al. Chronic hypoxia decreases synthesis of homologous recombination proteins and therapeutic resistance. Cancer Res 2008, 68:605-614.
36. Hegan D.C., Lu Y., Stachelek G.C., et al. Inhibition of poly(ADP-ribose) polymerase down-regulates BRCA1 and Rad51 in a pathway mediated by E2F4 and p130. Proc Natl Acad Sci U S A 2010, 107:2201-2206.
37. Rainey M.D., Charlton M.E., Stanton R.V., et al. Transient inhibition of ATM kinase is sufficient to enhance cellular sensitivity to ionizing radiation. Cancer Res 2008, 68:7466-7474.
38. Albert J.M., Cao C., Kim K.W., et al. Inhibition of poly(ADP-ribose) polymerase enhances cell death and improves tumor growth delay in irradiated lung cancer models. Clin Cancer Res 2007, 13:3033-3042.